1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1640
  5. Art Unit 1641
  6. Examiner Huynh

Examiner Huynh Phuong N

1641-HUYNH-PHUONG-N

Employment Information

Art Unit:1641 — Drug, bio-affecting and body treating compositions
Group:1640 — Immunology including antibodies, B&T lymphocytes, antigen presenting cells and Gram-positive/Negative Bacteria, Parasitic and Fungal Immunology
Classes: 424 — Drug, bio-affecting and body treating compositions
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
435 — Chemistry: molecular biology and microbiology
514 — Drug, bio-affecting and body treating compositions
600 — Surgery
455 — Telecommunications
Phone:(571) 272-0846
Email:phuong.huynh@uspto.gov
Location:VA 22314
Title:Pat Examnr Micrbiolgy
Service:26 years
Grade:GS-14

Grant Rate and Difficulty Ranking

68
3-Year Grant rate: 64% over 443 cases
Difficulty: Harder
Difficulty Percentile: 68th

With Examiner Huynh, you have a 64% chance of getting an issued patent by 3 years after the first office action. Examiner Huynh is a harder examiner and in the 68th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Huynh, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1641

Examiner Huynh's grant rate is higher than that of Art Unit 1641 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Huynh 1.9
Art Unit 1641 1.8

Interview Benefit

Grant Rate without Interview

Examiner Huynh has granted 209 of 357 cases without any applicant-requested interviews for a grant rate of 59%.

Grant Rate with Interview

Examiner Huynh has granted 74 of 86 cases with at least one applicant-requested interview for a grant rate of 86%.

Interview Benefit

With Examiner Huynh, conducting an interview increases your chance of getting a patent granted by 46%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
19023442 Albumin Protein Variants, Production Thereof And Uses Of Same Rejection information available with a Premium Stats subscription. See our pricing. Patented View
18298131 Compositions And Methods Related To Engineered Fc Constructs Abandoned View
17975353 Methods Of Use Of Anti-Cd37 Antibodies, Monoclonal Anti-Cd37 Antibodies Patented View
17854395 Motif-Specific And Context-Independent Antibodies That Specifically Bind To A Sumoylated Lysine-Containing Residue Patented View
17946791 Retinoic Acid Modified Lysosome Targeting Chimera Molecule, Preparation Method And Applications Thereof Patented View
18031781 Pharmaceutical Composition For Preventing Or Treating Lupus-Related Diseases Comprising Gip Derivative Or Long-Acting Conjugate Thereof Abandoned View
19256452 Fcrn/antigen-Binding Molecules And Methods Of Use Patented View
18495109 Cd33 Specific Chimeric Antigen Receptors For Cancer Immunotherapy Abandoned View
16390912 Fabs-In-Tandem Immunoglobulin And Uses Thereof Abandoned View
17783738 Stabile Conjugate Abandoned View
17809699 Plap-Cd3 Epsilon Bispecific Antibodies Abandoned View
18452699 Multivalent Binding Molecules Patented View
18744084 Cytostatic Conjugates With Integrin Ligands Abandoned View
18242154 Novel Antibody Format Abandoned View
17756797 Interferon-Associated Antigen Binding Proteins For Use In Treating Hepatitis B Infection Abandoned View
17730510 Protein Complex By Use Of A Specific Site Of An Immunoglobulin Fragment For Linkage Patented View
18349678 Cs1 Targeted Chimeric Antigen Receptor-Modified T Cells Patented View
17379761 Methods Of Producing Multimeric Proteins In Eukaryotic Host Cells Patented View
18459922 Anti-Cd40 Antibodies For Use In Prevention Of Graft Rejection Abandoned View
17561207 Antigen-Binding Molecule For Promoting Elimination Of Antigens Abandoned View
18054776 Binding Molecules With Modified J-Chain Patented View
17638642 Compositions And Methods For Delivery Of Nucleic Acids To Cells Patented View
18494165 Antigen Binding Molecules And Methods Of Use Thereof Abandoned View
18345750 Antigen-Binding Molecule Containing Modified Antibody Variable Region Patented View
18146269 Antibody-Alk5 Inhibitor Conjugates And Their Uses Patented View
18505921 Polynucleotide-Linked Bioconjugates And Methods Of Making And Using Abandoned View
18165233 Complement Factor D Antagonist Antibodies And Conjugates Thereof Patented View
18910445 Anti-Muc1* Antibody Drug Complexes And Uses Thereof Abandoned View
17150005 Methods For Treatment Of Refractory Generalized Myasthenia Gravis Patented View
16966823 Methods For Treating Facioscapulohumeral Muscular Dystrophy Patented View
18175786 Nanobody Based Imaging And Targeting Of Ecm In Disease And Development Patented View
17253821 Protein Biomarkers For Nephropathy And Applications Thereof Abandoned View
17534029 Bispecific Anti-Cd37 Antibodies, Monoclonal Anti-Cd37 Antibodies And Methods Of Use Thereof Patented View
18446406 Transglutaminase-Mediated Conjugation Abandoned View
18677564 Antibody-Drug Conjugates Targeting Folate Receptor Alpha And Methods Of Use Patented View
16536154 Tolerogenic Synthetic Nanocarriers For Antigen-Specific Deletion Of T Effector Cells Abandoned View
18326903 Compositions And Methods Of Treating Muscle Dystrophy Patented View
17434315 Antibody-Drug Conjugates Comprising Anti-Tm4sf1 Antibodies And Methods Of Using The Same Patented View
18316804 Multispecific Antibody Molecules Comprising Lambda And Kappa Light Chains Patented View
18462325 Process For The Preparation Of Pegylated Drug-Linkers And Intermediates Thereof Abandoned View
18410296 Drug Conjugates With Self-Stabilizing Linkers Having Improved Physiochemical Properties Abandoned View
15061096 Tolerogenic Synthetic Nanocarriers To Reduce Immune Responses To Therapeutic Proteins Abandoned View
18069151 Chimeric Polypeptides And Uses Thereof Patented View
17630685 Parvovirus Antibodies For Veterinary Use Patented View
17191634 Method For Improving The Benefit To A Subject Of A Therapy Or Therapeutic Agent Patented View
17307447 Antibody-Conjugates For Targeting Of Tumours Expressing Trop-2 Patented View
18585676 Compositions And Methods Comprising Antibodies That Bind To Covalent Peptide Conjugates Patented View
18169767 Methods And Materials For Assessing Response To Plasmablast- And Plasma Cell-Depleting Therapies Patented View
18347280 Engineered Polypeptide Conjugates Using Transglutaminase Abandoned View
17053728 Bispecific Antibodies With Cleavable C-Terminal Charge-Paired Tags Patented View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.